Association of circulating tumor cells (CTCs) with immune checkpoint inhibitor (ICI) responses in metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Zhang, T. [1 ]
Poellmann, M. [2 ]
Park, S-J. [2 ]
Bu, J. [2 ]
Zhao, R. [1 ]
Zhou, Q. [1 ]
Agarwal, A. [3 ]
Parks, J. [4 ]
Reyes-Martinez, M. [4 ]
Armstrong, A. J. [5 ]
George, D. J. [4 ]
Wang, A. Z. [6 ]
Hong, S. [2 ]
机构：
[1] UTSW Univ Texas Southwestern Med Ctr, Internal Med, Dallas, TX USA
[2] Univ Wisconsin, Pharmaceut Sci, Madison, WI USA
[3] Univ North Carolina Chapel Hill, Sch Med, Chapel Hill, NC USA
[4] Duke Univ Med Ctr, Duke Canc Ctr, Med, Durham, NC USA
[5] Duke Canc Ctr, Med, Durham, NC USA
[6] UTSW Univ Texas Southwestern Med Ctr, Radiat Oncol, Dallas, TX USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1475P
引用
收藏
页码：S1221 / S1221
页数：1
相关论文
共 50 条
  • [1] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
    Zhu, Jason
    Pabla, Sarabjot
    Labriola, Matthew
    Gupta, Rajan T.
    McCall, Shannon
    George, Daniel J.
    Dressman, Devin
    Glenn, Sean T.
    Nesline, Mary
    George, Saby
    Morrison, Carl
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [2] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
    Zhu, Jason
    Pabla, Sarabjot
    Labriola, Matthew
    Gupta, Rajan T.
    McCall, Shannon
    George, Daniel J.
    Dressman, Devin
    Glenn, Sean
    Nesline, Mary
    George, Saby
    Morrison, Carl
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
    Zhu, Jason
    Pabla, Sarabjot
    Labriola, Matthew
    Gupta, Rajan T.
    McCall, Shannon
    George, Daniel J.
    Dressman, Devin
    Glenn, Sean
    George, Saby
    Morrison, Carl
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Gene expression profile of circulating tumor cells (CTCs) in clear cell metastatic renal cell carcinoma (mRCC)
    Iacovelli, R.
    Nicolazzo, C.
    Petracca, A.
    Risi, E.
    Cortesi, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [5] Association between circulating cytokines expression patterns and outcomes to immune-checkpoint (ICI)-based regimens in metastatic renal cell carcinoma (mRCC)
    Linville, Laura Meili
    Feinaj, Ardit
    Nathani, Kaizen
    Singla, Nirmish
    Yarchoan, Mark
    Markowski, Mark Christopher
    Carducci, Michael Anthony
    Munjal, Kabeer
    Thoburn, Christopher
    Gizzi, Jennifer
    Kao, Chester
    Elias, Roy
    Ged, Yasser
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Salvage immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) combination therapy for metastatic renal cell carcinoma (mRCC).
    Parikh, Anish B.
    Psutka, Sarah P.
    Yang, Yuanquan
    Collier, Katharine
    Miah, Abdul
    Li, Mingjia
    Mori-Vogt, Sherry
    Hinkley, Megan
    Orcutt, Delaney
    Trott, Elliott
    Gross, Evan
    Hussey, Duncan
    Kramer, Joel
    Oliva, Kaylee
    Mortazavi, Amir
    Monk, Paul
    Folefac, Edmund
    Clinton, Steven K.
    Yin, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] RACIAL DIFFERENCES IN OUTCOMES FOR METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS MANAGED ON IMMUNE-CHECKPOINT INHIBITOR (ICI) THERAPY
    Olsen, T. Anders
    Martini, Dylan
    Goyal, Subir
    Liu, Yuan
    Evans, Sean
    Magod, Benjamin
    Brown, Jacqueline
    Yantorni, Lauren
    Russler, Greta
    Caulfield, Sarah
    Goldman, Jamie
    Nazha, Bassel
    Harris, Wayne
    Master, Viraj
    Kucuk, Omer
    Carthon, Bradley
    Bilen, Mehmet
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A133 - A133
  • [8] A real-world experience of immune checkpoint inhibitors (ICI) in metastatic renal cell carcinoma (mRCC)
    Elias, Roy
    Levonyak, Nicholas
    Christie, Alana
    Bowman, Isaac Alexander
    Kapur, Payal
    Hannan, Raquibul
    Hammers, Hans J.
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [9] Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).
    Dizman, Nazli
    Govindarajan, Ameish
    Zengin, Zeynep Busra
    Meza, Luis A.
    Tripathi, Nishita
    Sayegh, Nicolas
    Castro, Daniela V.
    Chan, Elyse H.
    Lee, Kyle O.
    Prajapati, Sweta R.
    Feng, Matthew I.
    Loo, Vivian
    Pace, Makala
    O'brien, Shea
    Bailey, Erin B.
    Barragan-Carrillo, Regina
    Chehrazi-Raffle, Alex
    Li, Xiaochen
    Agarwal, Neeraj
    Pal, Sumanta Monty
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [10] Efficacy of immune checkpoint inhibitors (ICI) treatment in special populations of metastatic renal cell carcinoma (mRCC)
    Araujo, Daniel Vilarim
    Malone, Eoghan Ruadh
    Sacher, Adrian G.
    Fallah-Rad, Nazanin
    Sridhar, Srikala S.
    Hansen, Aaron Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345